All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
A Multi-Center, Open Label Phase 1/2 Study Of Cyt-0851, An Oral Rad51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors
A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome
• What are the side effects of MGD006?
• What is the highest dose of MGD006 that can be given safely?
• How long does MGD006 stay in the blood?
• How long does it take for MGD006 to leave the body?
• Is MGD006 a possible treatment for AML?
An Open-label, First-in-human, Single Agent, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of SAR442085 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Phase 3 Accelerated BEP Trial: A Randomised Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP Trial)
A Phase II Trial of Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5-15 Brain Metastases
An Open-Label, Multiple-Dose, Dose- Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma
A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Surufatinib (HMPL-012), Previously Named Sulfatinib in Advanced Solid Tumors
Phase III Trial of Post-surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease
A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination with Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft Versus Host Disease
A Phase I/II, Open-label, Multicentre 2-part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle as Monotherapy or in Combination in Treatment-naïve or Relapsed/refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer
(Second Line) - RaPiDS
(Second Line) - RaPiDS
Structural and Functional Connectivity Changes in the Brain in Response to Diagnostic Nerve Blocks in Stroke Survivors
Identify changes in brain functional connectivity associated with diagnostic nerve blocks (DNB) to relieve spasticity in stroke survivors.
Primary Investigator: John McGuire, MD
Status: Currently Enrolling
IPSEN Abolish: Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort (AboLiSh)
Observational study to assess the longitudinal attainment of person centered and function related goals after one or more abobotulinum toxin A (aboBoNT-A) injections in the lower limb using the cumulated Goal Attainment Scaling -Leg (GASleg) T score in a real life clinical setting.
Primary Investigator: Nicholas Ketchum, MD
Status: Currently Enrolling
Merz: Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke (PLUS)
To test the safety and efficacy of NT 201 (Xeomin) for treating lower limb spasticity caused by stroke or traumatic brain injury in adult subjects, followed by an open label extension with or without combined upper limb treatment
Primary Investigator: Nicholas Ketchum, MD
Status: Currently Enrolling
SleepSmart: The Sleep for Stroke Management and Recovery Trial
Designed to evaluate ischemic stroke patients or patients with transient ischemic attack (TIA) for obstructive sleep apnea. Patients who qualify, will help assess whether continuous positive airway pressure (CPAP) for obstructive sleep apnea, after stroke, helps with recovery or helps prevent another stroke.
Status: Currently enrolling
ARCADIA: Atrial Cardiopathy and Antithrombotic Drugs in Prevention after Cryptogenic Stroke
A randomized, controlled trial of anticoagulation with Apixaban versus Aspirin for patients with embolic stroke of undetermined source, or ESUS, and evidence of atrial cardiopathy.
Status: Currently enrolling